Quince Therapeutics, Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference

Yeah. Our company was a small private company focused on this drug called LAM-001. It's a proprietary inhaled formulation of rapamycin, a DPI, one puff once a day. It was a long, arduous path, but we just reversed into Quince Therapeutics in May of this year, along with a $150 million PIPE. We're progressing the asset through multiple pulmonary indications where the mTOR pathway is clearly implicated. It's pretty exciting. We had a readout in pulmonary hypertension at ATS, May of this year, and our next readout will be coming in bronchiolitis obliterans syndrome post-transplant in first quarter of 2027.

Yeah. I think overarchingly, we are targeting a pathway that's highly implicated across a number of these disease states. It's hyperactivated, that has heretofore not been targeted. It's a totally different pathway, and it's turned out to be quite important across a number of different disease states. What has plagued the drug and prevented its adoption in oral form, which we know is available, is the systemic toxicities that come with that oral form of delivery. What we've created in this inhaled form, is a manner of delivering this directly to the pulmonary tissues at a tiny fraction of the oral dose, 1/20th of it. We are seeing very low systemic levels, and thus far quite a nice safety profile, which is allowing us to treat these patients where it's really needed.

Yeah. I can give you big picture. Keith can talk about everything he did to develop this. We know, really across multiple studies at this point, that at that 100 microgram dose, we are seeing systemically less than one nanogram per ML blood levels. That compares to the targeted blood levels with the typical oral rapamycin dose of 2 milligrams. They are targeting 5 to 15 nanograms systemically. We're seeing less than one-fifth to one-fifteenth those systemic levels seen with oral, and that's why it has been so well-tolerated. We also have nice evidence from animal models where the PK profile really mimics the profile we see in humans with our drug, that when delivered at, again, a fraction of the oral dose, we're seeing multifold exposure in the pulmonary tissue.

Maybe I'll turn it to Keith in terms of how difficult it was to make this.

No, thank you. Rapamycin is a large polyketide. It's actually a quite difficult molecule to formulate, and I think we've done a very good job in making a very stable commercial formulation that can treat these patients. More in particular, I think we've been very patient-focused as well. We've really designed this around a well-known, easy-to-use inhaler. There's low resistance. It doesn't take a lot of airflow to effectively extract, aerosolize the powder, and deposit to where it's needed, which is the deep lung.